HB1357
To Create The Rare Disease Advisory Council.
Last Action (May 1, 2023): Died in House Committee at Sine Die Adjournment
Sponsors
AI-Generated Summary
House Bill 1357 establishes a Rare Disease Advisory Council within the Arkansas Department of Human Services. The council's primary purpose is to provide expert clinical advice to the Arkansas Medicaid Drug Utilization Review Board regarding treatments for rare diseases. It is tasked with offering feedback to state agencies on issues impacting rare disease patients, such as access to care, insurance coverage, and pandemic preparedness. Additionally, the council will create and maintain publicly accessible resources concerning the research, diagnosis, and treatment of rare diseases. The bill mandates the composition of the 12-member council, which includes state officials, medical professionals, researchers, and patients or caregivers. The council is required to meet at least quarterly and submit an annual report to the Governor and the General Assembly detailing its activities and recommendations.
Potential Impact Analysis
Who Might Benefit?
The primary beneficiaries are patients in Arkansas diagnosed with rare diseases and their caregivers, who would gain a dedicated state-level platform to advocate for improved access to care, insurance coverage, and specialized treatment. Medical professionals, including physicians, geneticists, and researchers, also benefit by gaining a formal role in advising state policy and the Medicaid Drug Utilization Review Board. Furthermore, the state healthcare system may benefit from more informed, expert-driven decision-making regarding the efficacy and accessibility of treatments for rare conditions.
Who Might Suffer?
There are no specific groups identified as being directly and negatively impacted by the creation of this advisory council. However, state agencies, particularly the Department of Human Services, will incur additional administrative burdens, including the cost of staff, meeting facilities, and material support for the council. Furthermore, pharmaceutical companies or entities whose drugs are subjected to the Council's review process may face more rigorous scrutiny or advocacy regarding the clinical criteria and coverage policies associated with their products.
Get Notified
Receive an email when this bill's status changes.